IOMAI shareholders approve acquisition by Intercell
Iomai shareholders voted in favour of the acquisition at the special shareholder meeting
Intercell AG announced that the acquisition of Iomai by Intercell has been approved by the shareholders of Iomai in a special meeting which was held at Iomai's offices in Gaithersburg, MD. The merger was approved by 99,97 % of the votes cast - corresponding to more than 71% of the outstanding shares entitled to vote at the special meeting. After this important condition for the acquisition has been met, the closing of the transaction is expected within the next few days.
Iomai and Intercell AG entered into an Agreement and Plan of Merger (the Merger Agreement) whereby Iomai agreed to be acquired by Intercell AG subject to the terms and conditions of the Merger Agreement. Under the terms of the Merger Agreement, Intercell will acquire Iomai for USD 6.60 per share of Iomai's common stock representing a fully diluted equity value of Iomai of approximately USD 189 million (EUR 122 million). Iomai's public shareholders, representing approximately 59 percent of Iomai's outstanding common stock will receive cash. Certain of Iomai's largest shareholders (and their affiliates), together representing approximately 41 percent of Iomai's outstanding common stock, agreed to exchange their shares for Intercell stock at an exchange ratio corresponding to a value of USD 6.60 per share of Iomai common stock upon closing.
Other news from the department business & finance

Get the life science industry in your inbox
By submitting this form you agree that LUMITOS AG will send you the newsletter(s) selected above by email. Your data will not be passed on to third parties. Your data will be stored and processed in accordance with our data protection regulations. LUMITOS may contact you by email for the purpose of advertising or market and opinion surveys. You can revoke your consent at any time without giving reasons to LUMITOS AG, Ernst-Augustin-Str. 2, 12489 Berlin, Germany or by e-mail at revoke@lumitos.com with effect for the future. In addition, each email contains a link to unsubscribe from the corresponding newsletter.
Most read news
More news from our other portals
Last viewed contents
New Phase II Data on Millennium's Proteasome Inhibitor Holds Promise for Patients with Refractory Multiple Myeloma
The Scripps Research Institute Enters Major Five-Year $100 Million Collaboration with Pfizer
Skin-like tissue developed from human embryonic stem cells

Stopping and reversing Alzheimer's at an early stage - TUM study shows promising therapeutic approach
Vitamin D status associated with multiple sclerosis activity

First electric nanomotor made from DNA material - Synthetic rotary motors at the nanoscale perform mechanical work
Gastrotech signs licensing agreement with Eli Lilly following positive clinical data on compound for Irritable Bowel Syndrome
